Physician profile
Eric Pitts
NPI 1447675087
$12,554.10
in general payments reported to CMS, 2019-2025
33 companies · $2,141 in 2025
The $2,141 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $247 · 2021: $1,399 · 2022: $1,470 · 2023: $5,460 · 2024: $1,227 · 2025: $2,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,769 · Honoraria: $2,450 · Travel and Lodging: $1,581 · Education: $27.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,768.85 |
| Honoraria | $2,450.00 |
| Travel and Lodging | $1,580.59 |
| Education | $27.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $4,410.83 | 2020-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $1,251.62 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $1,191.50 | 2022-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $921.26 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $631.50 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Otsuka America Pharmaceutical, INC. | $575.84 | 2019-2025 | Jynarque, Voyxact |
| Novo Nordisk INC | $465.29 | 2021-2025 | Ozempic, Wegovy |
| Vifor Pharma, INC. | $438.82 | 2019-2023 | Veltassa, Korsuva |
| Ani Pharmaceuticals, INC. | $368.93 | 2022-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $332.44 | 2022-2025 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.77 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $227.76 | 2020-2025 | |
| Fresenius USA Marketing, INC. | $184.44 | 2020-2025 | Velphoro, Korsuva, Velphoro |
| Calliditas Therapeutics US INC. | $172.21 | 2023-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $158.24 | 2022-2023 | Benlysta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Medtronic, INC. | $124.99 | 2021 | |
| Alnylam Pharmaceuticals INC. | $104.18 | 2021-2025 | Oxlumo |
| Baxter Healthcare | $101.32 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $81.76 | 2019 | |
| Aurinia Pharma U.S., INC. | $65.14 | 2021-2025 | Lupkynis |
| Abbvie INC. | $47.79 | 2022 | |
| Opko Pharmaceuticals, LLC | $46.37 | 2019-2021 | |
| Amicus Therapeutics, INC. | $46.32 | 2020-2021 | |
| Travere Therapeutics, INC. | $42.84 | 2025 | Filspari |
| Genzyme Corporation | $38.23 | 2019-2022 | |
| Ardelyx, INC. | $26.52 | 2025 | Ibsrela |
| Vantive US Healthcare LLC | $24.02 | 2025 | Renal - Pd |
| Mallinckrodt Enterprises LLC | $18.57 | 2019 | |
| Akebia Therapeutics INC | $14.78 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.73 | 2022 | |
| Cormedix INC. | $14.03 | 2025 | Defencath |
| Janssen Pharmaceuticals, INC | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Pitts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.